CIPARS 2007 - Final Report

Appendix B – Additional Tables

The following information are important for the interpretation of tables presenting results on the distribution of minimum inhibitory concentrations (MIC; Appendix B.1 and B.2).

• Roman numerals I to IV indicate the ranking of human medicine importance as outlined by the Veterinary Drugs Directorate.
• The unshaded fields indicate the range tested for each antimicrobial in the plate configuration.
• Bold red numbers indicate the percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.
• Numbers to the right of the highest concentration in the tested range (i.e. bold red numbers in shaded fields) represent the percentage of isolates with growth in all wells within the tested range, indicating that the actual MICs were greater than the tested range of concentrations.
• Numbers at the lowest concentration in the tested range (i.e. blue numbers at the far left in unshaded fields) represent the percentage of isolates susceptible to the antimicrobial at the indicated or lower concentrations.
• Solid bars represent resistance breakpoints.
• Dotted bars represent susceptibility breakpoints.
• MIC 50 = MIC at which 50% of isolates were inhibited.
• MIC 90 = MIC at which 90% of isolates were inhibited.
• %R = Percentage of isolates that were resistant.

B.1 Antimicrobial Resistance in Humans

Table B.1.1. Distribution of Salmonella isolates from humans, by patient age and province; Surveillance of Human Clinical Isolates, 2007

Age (year)	Number (%) of isolates	Province	Number (%) of isolates
Less than 5	365 (11)	British Columbia	382 (12)
5 to 12	310 (9)	Alberta	397(12)
13 to 17	155 (5)	Saskatchewan	120 (4)
18 to 29	532 (16)	Manitoba	208 (6)
30 to 49	650 (20)	Ontario	1482 (45)
50 to 69	490 (15)	Québec	451 (14)
70 and more	241 (7)	Nova Scotia	85 (3)
Not specified	564 (17)	New Brunswick	130 (4)
		Prince Edward Island	17 (< 1)
		Newfoundland and Labrador	36 (1)
Total	3,308 (100)		3,308 (100)

Table B.1.2. Distribution of isolates of primary human Salmonella serovars from humans, by source; Surveillance of Human Clinical Isolates, 2007

Specimen source	Number (%) of isolates
	Enteritidis	Heidelberg	Newport	Paratyphi A and B	Typhi	Typhimurium	Other serovars	Total
Stool	731 (80)	240 (75)	103 (81)	9 (20)	26 (17)	559 (85)	784 (72)	2,452 (74)
Blood	23 (2)	22 (7)		20 (44)	99 (63)	17 (3)	26 (2)	207 (6)
Urine	17 (2)	11 (3)	6 (5)	2 (4)	2 (1)	14 (2)	52 (5)	104 (3)
Abscess							1 (< 1)	1 (< 1)
Anatomy part	1 (< 1)		1 (1)		1 (1)		3 (< 1)	6 (< 1)
Other body fluid	2 (< 1)				1 (1)	1 (< 1)	2 (< 1)	6 (< 1)
Unknown	136 (15)	46 (14)	17 (13)	14 (31)	27 (17)	67 (10)	225 (21)	532 (16)
Total	910 (100)	319 (100)	127 (100)	45 (100)	156 (100)	658 (100)	1,093 (100)	3,308 (100)

Table B.1.3. Distribution of minimum inhibitory concentrations (MICs; μg/mL) for antimicrobials in Salmonella Enteritidis isolates from humans; Surveillance of Human Clinical Isolates, 2007

Table B.1.3. - Text Equivalent

Table B.1.4. Distribution of minimum inhibitory concentrations (MICs; μg/mL) for antimicrobials in Salmonella Heidelberg isolates from humans; Surveillance of Human Clinical Isolates, 2007

Table B.1.4. - Text Equivalent

Table B.1.5. Distribution of minimum inhibitory concentrations (MICs; μg/mL) for antimicrobials in Salmonella Newport isolates from humans; Surveillance of Human Clinical Isolates, 2007

Table B.1.5. - Text Equivalent

Table B.1.6. Distribution of minimum inhibitory concentrations (MICs; μg/mL) for antimicrobials in Salmonella Paratyphi A and S. Paratyphi B isolates from humans; Surveillance of Human Clinical Isolates, 2007

Table B.1.6. - Text Equivalent

Table B.1.7. Distribution of minimum inhibitory concentrations (MICs; μg/mL) for antimicrobials in Salmonella Typhi isolates from humans; Surveillance of Human Clinical Isolates, 2007

Table B.1.7. - Text Equivalent

Table B.1.8. Distribution of minimum inhibitory concentrations (MICs; μg/mL) for antimicrobials in Salmonella Typhimurium isolates from humans; Surveillance of Human Clinical Isolates, 2007

Table B.1.8. - Text Equivalent

Table B.1.9. Distribution of minimum inhibitory concentrations (MICs; μg/mL) for antimicrobials in Salmonella “Other Serovars” isolates from humans; Surveillance of Human Clinical Isolates, 2007

Table B.1.9. - Text Equivalent

B.2 Antimicrobial Resistance in the Agri-Food Sector

Table B.2.1. Distribution of minimum inhibitory concentrations (MICs; μg/mL) for antimicrobials in Salmonella isolates from cattle; Surveillance of Animal Clinical Isolates, 2007

Table B.2.1. - Text Equivalent

Table B.2.2. Distribution of minimum inhibitory concentrations (MICs; μg/mL) for antimicrobials in Escherichia coli isolates from beef cattle; Abattoir Surveillance, 2007

Table B.2.2. - Text Equivalent

Table B.2.3. Distribution of minimum inhibitory concentrations (MICs; μg/mL) for antimicrobials in Escherichia coli isolates from beef, by province; Retail Meat Surveillance, 2007

Table B.2.3. - Text Equivalent

Table B.2.4. Distribution of minimum inhibitory concentrations (MICs; μg/mL) for antimicrobials in Campylobacter isolates from beef cattle, by Campylobacter species; Abattoir Surveillance, 2007

Campylobacter spp. include unidentified species, some of which may be intrinsically resistant to nalidixic acid.

Table B.2.4. - Text Equivalent

Table B.2.5. Distribution of minimum inhibitory concentrations (MICs; μg/mL) for antimicrobials in Salmonella isolates from chickens; Abattoir Surveillance, 2007

Table B.2.5. - Text Equivalent

Table B.2.6. Distribution of minimum inhibitory concentrations (MICs; μg/mL) for antimicrobials in Salmonella isolates from chicken, by province; Retail Meat Surveillance, 2007

Table B.2.6. - Text Equivalent

Table B.2.7. Distribution of minimum inhibitory concentrations (MICs; μg/mL) for antimicrobials in Salmonella isolates from chickens; Surveillance of Animal Clinical Isolates, 2007

Table B.2.7. - Text Equivalent

Table B.2.8. Distribution of minimum inhibitory concentrations (MICs; μg/mL) for antimicrobials in Escherichia coli isolates from chickens; Abattoir Surveillance, 2007

Table B.2.8. - Text Equivalent

Table B.2.9. Distribution of minimum inhibitory concentrations (MICs; μg/mL) for antimicrobials in Escherichia coli isolates from chicken, by province; Retail Meat Surveillance, 2007

Table B.2.9. - Text Equivalent

Table B.2.10. Distribution of minimum inhibitory concentrations (MICs; μg/mL) for antimicrobials in Campylobacter isolates from chicken, by Campylobacter species and province; Retail Meat Surveillance, 2007

Campylobacter spp. include unidentified species, some of which may be intrinsically resistant to nalidixic acid.

Table B.2.10. - Text Equivalent

Table B.2.11. Distribution of minimum inhibitory concentrations (MICs; μg/mL) for antimicrobials in Enterococcus isolates from chicken, by Enterococcus species and province; Retail Meat Surveillance, 2007

^a Resistance to quinupristin-dalfopristin and lincomycin is not reported for E. faecalis because E. faecalis is intrinsically resistant to these antimicrobials.

Table B.2.11. - Text Equivalent

Appendix B – Additional Tables is continued on the next page.